Autopsy report · NCT01813838

GFM-Acadesine: A Phase I-II Trial of Acadesine

“Renal toxicity”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 months before it started.
• Ran for about 2 years before it stopped.
• 5 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

Groupe Francophone des Myelodysplasies

Sponsor type

University, hospital or other

Conditions

SMD

Interventions

ACADESINE 140mg/kg/d; ACADESINE 210mg/kg/d; ACADESINE 315mg/kg/d

Participants

5

Sites

17

Countries

France

Trials that died the same way

• Phase I Trial of Brentuximab Vedotin for Refractory Chronic Graft-vs.-Host Disease (GVHD)
  “Toxicity” (67% match in meaning)
• Radiation Therapy, Cisplatin, Fluorouracil, and Cetuximab in Treating Patients With Locally Advanced Anal Cancer
  “Inadequate toxicity” (64% match in meaning)
• A Phase II Trial of Calcitriol and Naproxen in Patients With Recurrent Prostate Cancer
  “Extreme toxicity” (62% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.